Intelligence Platform

Patents

Browse 29,054 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12415995

Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferatio

Northwestern University · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12416006

Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use ther

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12416008

Compositions and methods of use for small-molecule regulation of CRISPR-Cas9 activity usin

The Regents of the University of Colorado, a Body Corporate · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12414907

Peptide having hair growth promoting activity and use thereof

CAREGEN CO., LTD. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415866

Monoclonal antibody inhibitor of Factor XIIa

Takeda Pharmaceutical Company Limited · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12414963

Treatment of sleep-wake disorders and neurodegenerative disease comprising modified resist

Northwestern University · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12414953

Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

Prelude Therapeutics, Incorporated · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415867

Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use

The Board of Regents of the University of Oklahoma · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12414911

Topical compositions and methods of use

MIRACLE FRUIT OIL L.L.C. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12409181

Treatment for aortic aneurysms

The Regents of the University of California · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12409188

Modulators of HSD17B13 expression

Ionis Pharmaceuticals, Inc. · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12409197

Synergistic bacterial compositions and methods of production and use thereof

Seres Therapeutics, Inc. · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12412764

Substrate-accommodating container

MIRAIAL CO., LTD. · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12410442

Compositions and methods for treating sensorineural hearing loss using otoferlin dual vect

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12410474

Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders

Northwestern University · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12410399

Compositions and methods for treating retinal diseases

The Regents of the University of California · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12410398

Methods of human retinal progenitor cell isolation and culture

The Regents of the University of California · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12410403

Methods and compositions for inducing hematopoietic cell differentiation

Fate Therapeutics, Inc. · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12410249

Low dose antibody-based methods for treating hematologic malignancies

Actinium Phamaceuticals, Inc. · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12410240

Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12410259

CD47 targeted therapies for the treatment of infectious disease

granted patent

US 12410418

Optimized engineered meganucleases having specificity for a recognition sequence in the He

Precision BioSciences, Inc. · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12410430

Modulating apolipoprotein (A) expression

Ionis Pharmaceuticals, Inc. · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12410225

Modulation of dendritic cell lineages

Orionis Biosciences, Inc · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted